WELCOME TO CONFIDENCE, EXTENDED

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.^{[1][2][3][4][5]}

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).^[5]

Instructions for use and handling of EYLEA 8 mg in patients with nAMD and DMO

^[5]

Disclaimer: These instructions are not complete. For full instructions, please download the instructions for use (IFU) card below and refer to the EYLEA 114.3 mg/mL Summary of Product Characteristics.

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.^[5]

Prescribing information for EYLEA® (aflibercept) can be found here.

Abbreviations

DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.